Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. It offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreatic biliary cancer, and ovarian cancer. The company sells its cancer diagnostic assays directly to oncologists and other physicians at private and group practices, hospitals, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Phone858-320-8200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$5.07 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date3/27/2019 (Estimated)
OptionableOptionable
Biocept (NASDAQ:BIOC) Frequently Asked Questions
What is Biocept's stock symbol?
Biocept trades on the NASDAQ under the ticker symbol "BIOC."
How were Biocept's earnings last quarter?
Biocept Inc (NASDAQ:BIOC) posted its quarterly earnings data on Tuesday, August, 14th. The medical research company reported ($2.70) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($3.30) by $0.60. The medical research company earned $0.82 million during the quarter, compared to the consensus estimate of $1.09 million. Biocept had a negative net margin of 715.42% and a negative return on equity of 456.20%. View Biocept's Earnings History.
When is Biocept's next earnings date?
What price target have analysts set for BIOC?
2 analysts have issued 1 year target prices for Biocept's stock. Their predictions range from $1.00 to $1.00. On average, they expect Biocept's share price to reach $1.00 in the next twelve months. This suggests that the stock has a possible downside of 5.7%. View Analyst Price Targets for Biocept.
What is the consensus analysts' recommendation for Biocept?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biocept in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Biocept.
Has Biocept been receiving favorable news coverage?
News headlines about BIOC stock have been trending somewhat negative this week, according to InfoTrie. The research group rates the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Biocept earned a coverage optimism score of -1.1 on InfoTrie's scale. They also assigned press coverage about the medical research company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an impact on the company's share price in the next few days.
Are investors shorting Biocept?
Biocept saw a decline in short interest in February. As of February 15th, there was short interest totalling 466,391 shares, a decline of 76.2% from the January 31st total of 1,957,896 shares. Based on an average daily volume of 1,888,253 shares, the days-to-cover ratio is presently 0.2 days. Currently, 11.3% of the company's stock are short sold. View Biocept's Current Options Chain.
Who are some of Biocept's key competitors?
What other stocks do shareholders of Biocept own?
Who are Biocept's key executives?
Biocept's management team includes the folowing people:
- Mr. Michael W. Nall, CEO, Pres & Director (Age 56)
- Mr. Timothy C. Kennedy, CFO, Sr. VP of Operations & Corp. Sec. (Age 61)
- Dr. Lyle J. Arnold, Sr. VP of R&D, Chief Scientific Officer and Member of Scientific Advisory Board (Age 72)
- Dr. Soon Kap Hahn Ph.D., Founder
- Mr. Pavel Tsinberg, Director of Technology Devel.
Who are Biocept's major shareholders?
Biocept's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Dimensional Fund Advisors LP (4.86%) and Dimensional Fund Advisors LP (4.86%). View Institutional Ownership Trends for Biocept.
Which institutional investors are buying Biocept stock?
How do I buy shares of Biocept?
Shares of BIOC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Biocept's stock price today?
One share of BIOC stock can currently be purchased for approximately $1.06.
How big of a company is Biocept?
Biocept has a market capitalization of $2.41 million and generates $5.07 million in revenue each year. The medical research company earns $-21,610,000.00 in net income (profit) each year or ($23.72) on an earnings per share basis.
What is Biocept's official website?
How can I contact Biocept?
Biocept's mailing address is 5810 Nancy Ridge Drive, San Diego CA, 92121. The medical research company can be reached via phone at 858-320-8200 or via email at [email protected]
MarketBeat Community Rating for Biocept (NASDAQ BIOC)
MarketBeat's community ratings are surveys of what our community members think about Biocept and other stocks. Vote "Outperform" if you believe BIOC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIOC will underperform the S&P 500 over the long term. You may vote once every thirty days.
